FDA Details Steps to Ensure Smooth Transition of IRBs

Clinical Trials Advisor
A A
Institutional review boards that assume oversight of a clinical trial from another IRB should give drugmakers an opportunity to address any concerns the receiving IRB has with the study before it is terminated or suspended, an FDA final guidance says.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00